These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 34221179)

  • 1. SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer.
    Bartsch R
    Memo; 2021; 14(3):247-251. PubMed ID: 34221179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
    Dormann C
    Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ESMO 2020: highlights in breast cancer.
    Bartsch R
    Memo; 2021; 14(2):184-187. PubMed ID: 33968263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
    Curigliano G; Mueller V; Borges V; Hamilton E; Hurvitz S; Loi S; Murthy R; Okines A; Paplomata E; Cameron D; Carey LA; Gelmon K; Hortobagyi GN; Krop I; Loibl S; Pegram M; Slamon D; Ramos J; Feng W; Winer E
    Ann Oncol; 2022 Mar; 33(3):321-329. PubMed ID: 34954044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
    Adams E; Wildiers H; Neven P; Punie K
    ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
    Schettini F; Venturini S; Giuliano M; Lambertini M; Pinato DJ; Onesti CE; De Placido P; Harbeck N; Lüftner D; Denys H; Van Dam P; Arpino G; Zaman K; Mustacchi G; Gligorov J; Awada A; Campone M; Wildiers H; Gennari A; Tjan-Heijnen V; Bartsch R; Cortes J; Paris I; Martín M; De Placido S; Del Mastro L; Jerusalem G; Curigliano G; Prat A; Generali D
    Cancer Treat Rev; 2022 Dec; 111():102468. PubMed ID: 36202026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
    Miles D; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Campone M; Bondarenko I; Nowecki Z; Errihani H; Paluch-Shimon S; Wardley A; Merot JL; Trask P; du Toit Y; Pena-Murillo C; Revelant V; Klingbiel D; Bachelot T;
    Ann Oncol; 2021 Oct; 32(10):1245-1255. PubMed ID: 34224826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer.
    Tolaney SM; DeMichele A; Takano T; Rugo HS; Perou C; Lynce F; Parsons HA; Santa-Maria CA; Rocque GB; Yao W; Sun SW; Mocci S; Partridge AH; Carey LA
    Future Oncol; 2024 Jun; ():1-21. PubMed ID: 38922307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
    Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
    Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series.
    Bergin ART; Luen SJ; Savas P; Boolell V; Cho D; Lynch J; Nott L; Stuart-Harris R; Teo LN; Yap SY; Loi S
    Asia Pac J Clin Oncol; 2019 Dec; 15(6):377-382. PubMed ID: 31321873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
    André F; Hee Park Y; Kim SB; Takano T; Im SA; Borges G; Lima JP; Aksoy S; Gavila Gregori J; De Laurentiis M; Bianchini G; Roylance R; Miyoshi Y; Armstrong A; Sinha R; Ruiz Borrego M; Lim E; Ettl J; Yerushalmi R; Zagouri F; Duhoux FP; Fehm T; Gambhire D; Cathcart J; Wu C; Chu C; Egorov A; Krop I
    Lancet; 2023 May; 401(10390):1773-1785. PubMed ID: 37086745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
    Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
    Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
    Bachelot T; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Bondarenko I; Paluch-Shimon S; Wardley A; Merot JL; du Toit Y; Easton V; Lindegger N; Miles D;
    Ann Oncol; 2019 May; 30(5):766-773. PubMed ID: 30796821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
    Rugo HS; Bardia A; Marmé F; Cortés J; Schmid P; Loirat D; Trédan O; Ciruelos E; Dalenc F; Gómez Pardo P; Jhaveri KL; Delaney R; Valdez T; Wang H; Motwani M; Yoon OK; Verret W; Tolaney SM
    Lancet; 2023 Oct; 402(10411):1423-1433. PubMed ID: 37633306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
    Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
    N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.
    Van Raemdonck E; Floris G; Berteloot P; Laenen A; Vergote I; Wildiers H; Punie K; Neven P
    Breast Cancer Res Treat; 2021 Jan; 185(1):183-194. PubMed ID: 32980945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASCO 2020: highlights in breast cancer.
    Bartsch R
    Memo; 2021; 14(1):58-61. PubMed ID: 33520003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience.
    Kolarov Bjelobrk I; Radic J; Trifunovic J; Pesic J; Vidovic V; Vranjkovic B; Petrovic N; Andrejic Visnjic B
    J Chemother; 2022 Jul; 34(4):264-271. PubMed ID: 34844517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
    Furlanetto J; Marmé F; Loibl S
    Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
    Dent RA; Cescon DW; Bachelot T; Jung KH; Shao ZM; Saji S; Traina TA; Vukovic P; Mapiye D; Maxwell MJ; Schmid P; Cortés J
    Future Oncol; 2023 Nov; 19(35):2349-2359. PubMed ID: 37526149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.